Characterization of the enterovirus 71 VP1 protein as a vaccine candidate

Journal of Medical Virology

Volumn 87, Issue 2, 2015, Pages 256-262

  Zhou, Shi Li ^a   Ying, Xiao Ling ^a   Han, Xue ^a   Sun, Xian Xun ^a,b   Jin, Qi ^b   Yang, Fan ^b  

^a JIANGHAN UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

EV71; HFMD; Immunogenicity; Vaccine; VP1 protein

Indexed keywords

INACTIVATED VIRUS VACCINE; INTERFERON RECEPTOR; INTERLEUKIN 10; PROTEIN VP1; CYTOKINE; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS PROTEIN; VIRUS VACCINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; DRUG PURIFICATION; DRUG SYNTHESIS; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; HUMORAL IMMUNITY; LD 50; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; RABBIT; SPLEEN CELL; TH1 CELL; TH2 CELL; VACCINATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; ENTEROVIRUS A; HAND, FOOT AND MOUTH DISEASE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MONONUCLEAR CELL; PASSIVE IMMUNIZATION; SECRETION (PROCESS); SPLEEN;

HUMAN ENTEROVIRUS 71; MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; ENTEROVIRUS A, HUMAN; FEMALE; HAND, FOOT AND MOUTH DISEASE; IMMUNITY, MATERNALLY-ACQUIRED; LEUKOCYTES, MONONUCLEAR; MICE, INBRED BALB C; SPLEEN; VACCINES, SUBUNIT; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 84919868694     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24018     Document Type: Article

References (35)

1. Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, Lai YH, Chiang YP, Chiang BL, Lee CY, Huang LM. 2006. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res 60:466-471.
2. Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. 2007. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics 120:e244-e252.
3. Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF, Chen CM. 2008. Expression of VP1 protein in the milk of transgenic mice: A potential oral vaccine protects against enterovirus 71 infection. Vaccine 26:2882-2889.
4. Cheng TS, Chang LK, Howng SL, Lu PJ, Lee CI, Hong YR. 2006. SUMO-1 modification of centrosomal protein hNinein promotes hNinein nuclear localization. Life Sci 78:1114-1120.
5. Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, Su IJ, Chong PC, Hsieh SM. 2013. A phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31:2471-2476.
6. Chuang SF, Chang CH, Yaman P, Chang LT. 2006. Influence of enamel wetness on resin composite restorations using various dentine bonding agents: Part I-Effects on marginal quality and enamel microcrack formation. J Dent 34:343-351.
7. Foo DG, Alonso S, Chow VT, Poh CL. 2007. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9:1299-1306.
8. Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O. 2002. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: Detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 46:621-627.
9. Ji H, Li L, Liu Y, Ge H, Wang X, Hu J, Wu B, Fu J, Zhang Z, Chen X, Zhang M, Ding Q, Xu W, Tang F, Zhou M, Wang H, Zhu F. 2012. Seroepidemiology of human enterovirus 71 and coxsackievirus A16 in Jiangsu province, China. J Virol 9:248.
10. Juhela S, Hyoty H, Lonnrot M, Roivainen M, Simell O, Ilonen J. 1998. Enterovirus infections and enterovirus specific T-cell responses in infancy. J Med Virol 54:226-232.
11. Kiener TK, Jia Q, Lim XF, He F, Meng T, Chow VT, Kwang J. 2012. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. J Virol 9:55.
12. Kolpe AB, Kiener TK, Grotenbreg GM, Kwang J. 2012. Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice. Virus Res 168:64-72.
13. Kuo RL, Shih SR. 2013. Strategies to develop antivirals against enterovirus 71. Virol J 10:28.
14. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. 2012. Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine 30:3295-3303.
15. Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang J. 2013. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vacc Immunother 9:1701-1705.
16. Lin TY, Chang LY, Hsia SH, Huang YC, Chiu CH, Hsueh C, Shih SR, Liu CC, Wu MH. 2002a. The 1998 enterovirus 71 outbreak in Taiwan: Pathogenesis and management. Clin Infect Dis 34:S52-S57.
17. Lin YC, Wu CN, Shih SR, Ho MS. 2002b. Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 20:2485-2493.
18. Liu JN, Wang W, Duo JY, Hao Y, Ma CM, Li WB, Lin SZ, Gao XZ, Liu XL, Xu YF, Xu WB, Qin C, Zhang LF. 2010. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28:7444-7451.
19. Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, Liang Z, Mao Q, Wang L, Dong C, Liao Y, Guo L, Yang E, Pu J, Yue L, Zhou Z, Li Q. 2013. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS ONE 8:e54451.
20. Mao LX, Wu B, Bao WX, Han FA, Xu L, Ge QJ, Yang J, Yuan ZH, Miao CH, Huang XX, Zhang C, Xu H. 2010. Epidemiology of hand, foot, and mouth disease and genotype characterization of enterovirus 71 in Jiangsu, China. J Clin Virol 49:100-104.
21. McMinn PC. 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. Fems Microbiol Rev 26:91-107.
22. Meng FY, Li JX, Li XL, Chu K, Zhang YT, Ji H, Li L, Liang ZL, Zhu FC. 2012. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: An open label, phase 1 clinical trial. Hum Vacc Immunother 8:668-674.
23. Nicklin MJ, Krausslich HG, Toyoda H, Dunn JJ, Wimmer E. 1987. Poliovirus polypeptide precursors: Expression in vitro and processing by exogenous 3C and 2A proteinases. Proc Natl Acad Sci USA 84:4002-4006.
24. Sato C, Syoji M, Ueki Y, Sato Y, Okimura Y, Saito N, Kikuchi N, Yagi T, Numakura H. 2006. Isolation of enterovirus 71 from patients with hand, foot and mouth disease in a local epidemic on March 2006, in Miyagi prefecture, Japan. Jpn J Infect Dis 59:348.
25. Schmidt NJ, Lennette EH, Ho HH. 1974. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129:304-309.
26. Singh S, Chow VT, Phoon MC, Chan KP, Poh CL. 2002. Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers. J Clin Microbiol 40:2823-2827.
27. Tee KK, Takebe Y, Kamarulzaman A. 2009. Emerging and re-emerging viruses in Malaysia, 1997-2007. Int J Infect Dis 13:307-318.
28. Tung WS, Bakar SA, Sekawi Z, Rosli R. 2007. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5:6.
29. Wang M, Jiang S, Wang Y. 2013a. Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice. Biochem Bioph Res Co 430:387-393.
30. Wang Y, Qing J, Sun Y, Rao Z. 2013b. Suramin inhibits EV71 infection. Antivir Res 103C:1-6.
31. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. 2001. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20:895-904.
32. Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, He Y, Bu G, Zhou S, Wang J, Qi J. 2009. Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 47:2351-2352.
33. Yang C, Deng C, Wan J, Zhu L, Leng Q. 2011. Neutralizing antibody response in the patients with hand, foot and mouth disease to enterovirus 71 and its clinical implications. Virol J 8:306.
34. Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ. 2000. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7:523-528.
35. Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, Ji F, Wang XJ, Gao YJ, Chen L, An HQ, Li DX, Wang SW, Xu AQ, Wang ZJ, Xu WB. 2009. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 44:262-267.